The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
The firms intend to seek CE marking and US Food and Drug Administration clearance for the test.
The company's microchip-based technology will detect viral and bacterial genetic material using both isothermal amplification and electrochemical measurements.
The test detects and differentiates respiratory syncytial virus and human metapneumovirus on the firm's Solana rapid molecular platform.
The assay runs on the Panther Fusion system, which combines transcription-mediated amplification, real-time TMA, and real-time PCR with full sample-to-result automation.
The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
The firm said that its test is the first on the market to detect RSV infection at the point of care in 13 minutes or less.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.